AI-generated analysis. Always verify with the original filing.
Ensysce Biosciences, Inc. received a Nasdaq Deficiency Letter on February 25, 2026, for failing to meet the Minimum Bid Price requirement of $1.00 per share under Listing Rule 5550(a)(2), as the bid price closed below $1.00 for 30 consecutive business days. The Company has 180 calendar days until August 24, 2026, to regain compliance by achieving a $1.00 closing bid price for at least 10 consecutive business days, with no immediate effect on its Nasdaq Capital Market listing under symbol ENSC.